franckreporter
- Citi has resumed its coverage of Ligand Pharmaceuticals (LGND) with a buy rating saying that its acquisition of XOMA Royalty adds a significant number of late-stage assets as well as a steady royalty stream.
- The acquisition, with an equity value
